Decoding PRTFDC1's Role in Lung Adenocarcinoma: From Gene Expression to Clinical Implications

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Lung Adenocarcinoma (LUAD) is a major cause of cancer mortality.
• Identifying novel biomarkers for LUAD prognosis and treatment is crucial.
• Phosphoribosyl Transferase Domain Containing 1 (PRTFDC1) function in LUAD is not well understood.

Purpose of the Study:

• To investigate the role of PRTFDC1 in LUAD.
• To evaluate PRTFDC1 as a potential prognostic biomarker in LUAD.
• To explore the association of PRTFDC1 with clinical characteristics, immune infiltration, and drug response in LUAD.

Main Methods:

• Bioinformatic analysis of PRTFDC1 gene expression in 539 LUAD and 59 normal lung tissues from TCGA.
• Correlation analysis of PRTFDC1 expression with clinical data, immune infiltration, Tumor Mutation Burden (TMB), and drug responsiveness.
• Experimental validation using LUAD cell lines (A549, HCC-78) with PRTFDC1 overexpression, followed by proliferation and cell cycle assays.

Main Results:

• PRTFDC1 expression is significantly higher in LUAD tissues than in normal tissues.
• Elevated PRTFDC1 correlates with poorer Progression-Free Survival (PFS) and Disease-Specific Survival (DSS) in LUAD patients.
• PRTFDC1 overexpression promotes LUAD cell proliferation and cell cycle progression, potentially mediated by Threonine Tyrosine Kinase (TTK).

Conclusions:

• PRTFDC1 serves as an independent prognostic marker for LUAD, impacting tumor progression and immune response.
• The association with TTK suggests a mechanistic link to cell proliferation.
• PRTFDC1 is a promising biomarker for LUAD prognosis and targeted therapy development.